@FiercePharma: Glenmark pulls 7 lots of contraceptive pills on a packaging error that could cause incorrect dosing/pregnancy risk. Article | Follow @FiercePharma
> Valeant Pharmaceuticals ($VRX) posted fourth-quarter profits, aided by growth in its dermatology business and added sales from newly acquired companies. Report
> Gedeon Richter, Hungary's largest drugmaker, said its Esmya drug won European regulatory approval for pre-operative treatment of uterine fibroids, an indication expected to net $134 million in peak sales. News
> Novartis ($NVS) said its cancer drug Glivec won European approval for three years of treatment after surgery in patients with certain gastrointestinal tumors. Release
> Access Pharmaceuticals said MuGard, its oral mucositis drug, won marketing approval in China, where it will be sold by partner Rhei Pharmaceuticals. Item
> Ear treatment specialist Otic Pharma raised $4.3 million from Orbimed to develop foam-based treatments for people and dogs. Article
Biotech News
@FierceBiotech: Brain switch turns 'on' when danger hits, 'off' when threat passes. Item | Follow @FierceBiotech
@JohnCFierce: MDV3100 release this a.m. includes new survey on specialists, desire for new prostate cancer drugs. Release | Follow @JohnCFierce
@RyanMFierce: Help me find the world's smartest biotech techies for new Fierce special report: Report | Follow @RyanMFierce
@FierceMedDev: AngioDynamics' new chief playing offense and ready for risk. Via @Business_Review. Article | Follow @FierceMedDev
> Study finds no (unique) industry bias in published trial results. Report
> GSK lassos rare disease program in Angiochem tie-up. Story
> FDA rejects Columbia Labs' gel to prevent preterm births. News
Medical Devices News
> Autonomic tackles migraines with neurostimulation tech. Article
> InSightec scores $13.75M from GE. Story
> Wright sees quarterly sales, net income drop. News
> Can U.S. ensure access to a 2nd diagnostic test? Item
IT News
> Roche getting entire workforce to use Google Apps. Story
> Startup aims to tap wisdom of the crowd for low-cost drug trials. Article
> J&J hires Selventa to build computerized models for personalized medicine. News
And Finally... Scientists have identified a key suspect in metabolic syndrome, which increases risks of diabetes and heart disease. Report